Actively Recruiting
Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma
Led by Zhifeng Tian,MD · Updated on 2025-01-30
38
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
With the optimization of the dosage form of irinotecan, the replacement of ordinary irinotecan with irinotecan liposomes should improve the safety and the expected efficacy. Therefore, an exploratory study on the treatment progress of irinotecan liposomes combined with bevacizumab for recurrent brain glioma should be conducted. To evaluate the efficacy and safety of irinotecan liposomes combined with bevacizumab in the treatment of progressive/recurrent brain glioma, so as to provide more treatment options for patients with brain glioma.
CONDITIONS
Official Title
Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years old
- Diagnosed with glioma by histology
- Disease progression after first-line therapy including postoperative recurrence or inability to undergo surgery/radiotherapy
- No previous treatment with irinotecan or irinotecan liposomes
- At least one measurable or evaluable lesion according to RANO criteria
- ECOG performance status of 0 to 1
- Good bone marrow and organ function with specific laboratory thresholds
- Expected survival of at least 3 months
- Able to understand the study and provide informed consent
You will not qualify if you...
- Allergy to the investigational drugs or their excipients
- Known or suspected central nervous system metastasis
- Use of potent CYP3A, CYP2C8, or UGT1A1 enzyme modulators that cannot be stopped 2 weeks before enrollment
- Signs or symptoms of intestinal obstruction
- Other malignant tumors within past 5 years except certain cured cancers
- Pregnant or lactating women or those refusing contraception
- Considered unsuitable for the study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The central Hospital of Lishui City
Lishui, Zhejiang, China, 323000
Actively Recruiting
Research Team
Z
Zhifeng Tian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here